Literature DB >> 10498136

Usefulness of tilt test-induced patterns of heart rate and blood pressure using a two-stage protocol with glyceryl trinitrate provocation in patients with syncope of unknown origin.

A S Kurbaan1, A C Franzén, T J Bowker, T R Williams, S Kaddoura, M E Petersen, R Sutton.   

Abstract

This study assesses the vasovagal collapse pattern changes, i.e, heart rate (HR) and arterial blood pressure (BP) with a 2-stage tilt-test protocol using glyceryl trinitrate (GTN) provocation. With use of the 45-minute 60 degrees head-up Westminster protocol, 102 consecutive patients were studied. Sublingual GTN 300 microg was given to those with a negative passive tilt. Heart rate and BP patterns were classified according to the Vasovagal International Study classification (VASIS) and then compared between those with a positive passive tilt and those with a positive tilt after having been given GTN. Twelve patients did not tolerate tilt testing, and 16 had a negative response despite taking GTN. Thirty-five patients (20 women and 15 men, mean age 45 +/- 21 years [mean +/- SD]) did not take GTN and 38 (26 women and 12 men, mean age 53 +/- 22 years) had positive passive test results. When comparing the VASIS classification between the 2 groups, results showed: type 1, mixed BP and HR decreased without severe bradycardia (31% [passive] vs 54% [with GTN], p = NS); type 2A, BP decreased before HR decreased (20% vs 22%, p = NS); type 2B, HR decreased before or coincident with BP (34% vs 8%, p = 0.003); type 3, BP decreased without HR decrease (9% vs 0%, p = NS); exception 1, chronotropic incompetence (0% vs 13%, p = 0.026); and exception 2, excessive HR increase (6% vs 3%, p = NS). Thus, GTN use increases frequency of positive results from 34% to 73%. Older people with chronotropic incompetence, who may benefit from pacing, were identified. In younger people there was an increase in those with cardioinhibition.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10498136     DOI: 10.1016/s0002-9149(99)00413-0

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  7 in total

1.  Determining the optimal pacing intervention rate for vasovagal syncope.

Authors:  A S Kurbaan; A C Franzén; Z Stack; D Heaven; G Mathur; R Sutton
Journal:  J Interv Card Electrophysiol       Date:  2000-12       Impact factor: 1.900

2.  Clinical predictors of head-up tilt test outcome during the nitroglycerin phase.

Authors:  Massimo Iacoviello; Cinzia Forleo; Pietro Guida; Marco Matteo Ciccone; Sandro Sorrentino; Valentina D'Andria; Mariligia Panunzio; Stefano Favale
Journal:  Clin Auton Res       Date:  2009-06-30       Impact factor: 4.435

3.  Tilt testing with combined lower body negative pressure: a "gold standard" for measuring orthostatic tolerance.

Authors:  Clare L Protheroe; Henrike Rianne J C Ravensbergen; Jessica A Inskip; Victoria E Claydon
Journal:  J Vis Exp       Date:  2013-03-21       Impact factor: 1.355

4.  Right insular atrophy in neurocardiogenic syncope: a volumetric MRI study.

Authors:  J B Kim; S-i Suh; W-K Seo; S-B Koh; J H Kim
Journal:  AJNR Am J Neuroradiol       Date:  2013-07-04       Impact factor: 3.825

5.  Short pain-provoked head-up tilt test for the confirmation of vasovagal syncope.

Authors:  Ivan Adamec; Antonija Mišmaš; Dinka Zaper; Anamari Junaković; Sanja Hajnšek; Mario Habek
Journal:  Neurol Sci       Date:  2012-06-21       Impact factor: 3.307

6.  Prospective Evaluation of Autonomic Dysfunction in Post-Acute Sequela of COVID-19.

Authors:  Sameer M Jamal; David B Landers; Steven M Hollenberg; Zoltan G Turi; Taya V Glotzer; Jana Tancredi; Joseph E Parrillo
Journal:  J Am Coll Cardiol       Date:  2022-04-02       Impact factor: 27.203

Review 7.  Pubertal Hormonal Changes and the Autonomic Nervous System: Potential Role in Pediatric Orthostatic Intolerance.

Authors:  Kassandra E Coupal; Natalie D Heeney; Brooke C D Hockin; Rebecca Ronsley; Kathryn Armstrong; Shubhayan Sanatani; Victoria E Claydon
Journal:  Front Neurosci       Date:  2019-11-12       Impact factor: 4.677

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.